Izgrev

Hydrochlorothiazide and Irbesartan, the active ingredients in Izgrev, are a thiazide diuretic and an angiotensin II receptor blocker presented as oral tablets for systemic use. The combination is indicated for managing hypertension and associated fluid retention.

GNH USA supplies Izgrev as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Izgrev is manufactured under EU GMP guidelines, ensuring batch consistency and patient safety.

Izgrev combines a thiazide diuretic and an angiotensin II receptor blocker to treat conditions related to elevated blood pressure and fluid overload.

Hypertension: lowers systolic and diastolic pressure, helping prevent cardiovascular complications. Edema: enhances urinary sodium and water excretion, reducing swelling associated with heart failure or renal disease. Cardiovascular risk reduction: improves overall blood pressure control, contributing to decreased risk of stroke and myocardial infarction.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Increased frequency of urination. - Mild headache. - Electrolyte disturbances such as low potassium. - Fatigue or weakness. - Transient rise in blood urea nitrogen. Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance. - Angioedema or swelling of the face, lips, or throat. - Acute kidney injury or significant rise in serum creatinine. - Hyperkalemia, particularly when combined with potassium‑sparing agents. - Allergic skin reactions, including rash or Stevens‑Johnson syndrome.

Before initiating therapy, patients should be evaluated for renal function, electrolyte status, and blood pressure stability.

- Monitor electrolytes: regular checks of sodium, potassium, and magnesium are advised. - Assess renal function: evaluate serum creatinine and eGFR periodically. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid in severe hypotension: the drug can exacerbate low blood pressure. - Pregnancy safety unknown: discuss risks with a healthcare professional. - Store at below 25°C: keep in the original pack, protect from moisture.

Izgrev may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid): - Lithium: increased lithium levels may cause toxicity. - ACE inhibitors or other ARBs: combined use can lead to severe hyperkalemia and renal impairment. - Potassium‑sparing diuretics: risk of dangerous potassium elevation. Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.